| HOME >> BIOLOGY >> TECHNOLOGY |
New DNA-Based Test Produces Decisive Result Within Minutes
PORTON DOWN, England, November 9 /PRNewswire/ -- Enigma Diagnostics, the life sciences company developing rapid molecular diagnostics and detection systems, announces that it has successfully completed a project commissioned by the Defence Science and Technology Laboratory (Dtsl) to develop a rapid, point-of-care diagnostic system for screening and diagnosis(1) of Chlamydia infections, the most common treatable sexually transmitted infection (STI) in the UK. The project was designed to meet the needs of the UK National Chlamydia Screening Programme (NCSP), part of the National Strategy for Sexual Health and HIV.
(Photo: http://www.newscom.com/cgi-bin/prnh/20071109/281128 )
Enigma has developed a specific DNA test (assay), reagents and instrumentation capable of rapidly detecting Chlamydia trachomatis DNA from multiple urine and, uniquely, swab samples at the point of care (PoC), i.e. in a clinic or outreach centre. Feasibility of the assay has been proven in the laboratory and the product specifications have been validated with sexual health professionals.
The new system will be based on Enigma's fully-automated diagnostics platform, which uses real-time polymerase chain reaction (PCR) technology to detect bacterial target DNA in samples and provides definitive results in a matter of minutes, enabling immediate treatment as necessary. The system will also be very simple to use, requiring minimal training and experience, and importantly will provide 'gold standard' laboratory quality results thereby reducing the need for samples to be sent to a laboratory for analysis. Other point of care diagnostics products for Chlamydia are known to give unreliable results.
John McKinley, Chairman of Enigma Diagnostics, said: "This successfully
completed contract with the UK Government demonstrates the
'/>"/>
| SOURCE Enigma Diagnostics Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
2. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
3. Strategic Diagnostics Updates Roth Conference Presentation Time
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
8. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
9. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
10. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
11. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |